PUBLIC CITIZEN for PUBLIC CITIZEN
What was lobbied
8 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
tax transparency and progressive revenue raisers, Lobby meeting with Senator Warner, financial transaction taxes, tax filing simplification. Forthcoming Bright Lines Project legislation, Bright Lines project, Nonprofit hospital policies.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSAN ELAINE HARLEY | — |
| EMILY PETERSON CASSIN | — |
| ROBERT STEWART | — |
Banking BAN
Financial reform, crypto currency legislation, bills slated for hearing and mark-up in House Financial Services Committee on 2/8 and 2/28, bills to deregulate securities underwriting, executive compensation reform, preventing future bank failures.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BARTLETT NAYLOR | — |
Civil Rights/Civil Liberties CIV
Lobbying for a rule making banning forced arbitration in financial products.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARTHA PEREZ-PEDEMONTI | — |
Consumer Issues/Safety/Products CSP
H.R. 6107 Stop Corporate Capture Act, regulatory reform, potential cryptocurrency legislation, Regulatory reform, CSS Lobby meeting, Stop Corporate Capture Act, REINS Act, access to justice and product safety, Consumer Products - children, S.2710 Open App Markets Act and S.2992 American Innovation and Choice Online Act, antitrust/competition policy, anti-monopoly issues, protecting consumers against forced arbitration. Commercial Surveillance Rule-making, Financial Data privacy bill - oppose, Kids internet privacy and safety bills, forthcoming comprehensive/kids privacy bills, privacy issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSAN ELAINE HARLEY | — |
| MATT KENT | — |
| BARTLETT NAYLOR | — |
| MARTHA PEREZ-PEDEMONTI | — |
| EMILY PETERSON CASSIN | — |
| ELIZABETH SKERRY | — |
Government Issues GOV
Banning congressional insider trading, H.J.Res.1 -- constitutional amendment to overturn Citizens United., Ban on congressional stock trading (TRUST in Congress Act), House rules package regarding the Office of Congressional Ethics (H.Res.5), Ban congressional stock trading activity (consensus bill), HUMBLE Act (no bill number yet), Office of Congressional Ethics, rules change (H.Res.5), Stop Foreign Money in American Elections Act (no bill number yet), Ban congressional stock trading (no bill number yet), Office of Congressional Ethics (OCE), Prohibition on Financial Trading on Government Property Act (no bill number yet), Prohibition on Financial Trading on Government Property Act (no bill number yet), Ban congressional stock trading, Banning congressional stock trading, Judiciary Act of 2023, DISCLOSE Act, End congressional stock trading (HR 345, HR 1679, no bill number in Senate yet), Judiciary Act (no bill number yet), ZOMBIE Act (no number yet),
| Lobbyist | Covered position, as disclosed |
|---|---|
| CRAIG HOLMAN | — |
Health Issues HCR
S 4204 and HR 1976, Medicare for All, private equity in health care, Oversight of private equity in health care, Healthcare Ownership Transparency Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| EAGAN KEMP | — |
Labor Issues/Antitrust/Workplace LBR
Heat stress, outline remarks for speaking at NACOSH meeting re: OSHA Heat rule process failings, met with Rep. Scholten and Rep Martinez - intro discussion of heat stress, Sunlight on Workplace Harassment bill.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JULEY FULCHER | — |
Pharmacy PHA
insulin pricing; drug launch prices; access terms for medicines w/ R&D funded by USG; R&D cost transparency; alternative pharmaceutical R&D models; pandemic vaccine manufacturing, IRA implementation, telehealth and pharmaceuticals, U.S. government support for the mRNA Hub program; pandemic vaccine manufacturing, , FDA policies impacting drug prices and spending; executive licensing authorities to lower drug prices , IRA drug price negotiation implementation, IRA drug price negotiation implementation, U.S. government support for the mRNA Hub , Bayh-Dole domestic manufacturing requirements, Biosimilar Red Tape Elimination Act, executive licensing and demonstration authorities to lower drug prices; IRA drug price negotiation implementation, IRA drug price negotiation implementation, IRA drug price negotiation implementation, IRA drug price negotiation implementation, IRA drug price negotiation implementation; Biosimilar Red Tape Elimination Act , Prescription Drug Access and Affordability Act, Prescription Drug Price Relief Act, S.79 (Interagency Patent Coordination and Improvement Act); S.113 (Prescription Pricing for the People Act); S.142 (Preserve Access to Affordable Generics and Biosimilars Act); S.148 (Stop STALLING Act); S.150 (Affordable Prescriptions for Patients Act), S.79 (Interagency Patent Coordination and Improvement Act); S.113 (Prescription Pricing for the People Act); S.142 (Preserve Access to Affordable Generics and Biosimilars Act); S.148 (Stop STALLING Act); S.150 (Affordable Prescriptions for Patients Act; e, TRACK Act, TRACK Act, U.S. government support for the mRNA Hub program, U.S. government support for the mRNA Hub program; public vaccine manufacturing, Affordable Pricing for Taxpayer-Funded Prescription Drugs Act, Affordable Pricing for Taxpayer-Funded Prescription Drugs Act; FDA-PTO coordination, covid vaccine pricing; executive licensing and demonstration authorities to lower drug prices; U.S. government support for the mRNA Hub program, insulin pricing legislation, IRA drug price negotiation implementation, IRA drug price negotiation implementation; Emergency Access to Insulin Act; S.79; S.113; S.142; S.148; S.150; IRA negotiation delay periods and other measures; U.S. government support for the mRNA Hub program; IRA negotiation delay periods, IRA drug price negotiation implementation; NDAA drug pricing and licensing; insulin cost & pricing legislation; S.79; S.113; S.142; S.148; S.150; IRA negotiation delay periods and other measures; U.S. government support for the mRNA Hub program, NDAA drug pricing, licensing and transparency requirements; IRA negotiation delay periods and other measures; U.S. government support for the mRNA Hub program , U.S. government support for the mRNA Hub program, executive licensing authorities to lower drug prices, Insulin for All Act; IRA drug price negotiation implementation, Insulin for All Act; IRA drug price negotiation implementation; legislation to strengthen IRA drug pricing provisions; U.S. government support for the mRNA Hub program, IRA drug price negotiation implementation, IRA drug price negotiation implementation and legislative improvements, legislation to strengthen IRA drug pricing provisions, NDAA medicines licensing, pricing and contract transparency provisions; Insulin for All Act, PASTEUR Act, Pharmaceutical Research Transparency Act; IRA drug price negotiation implementation; U.S. government support for the mRNA Hub program; access to U.S. government funded medicines and vaccines, Protecting Consumer Access to Generic Drugs Act; U.S. government support for the mRNA Hub program; access to U.S. government funded medicines and vaccines, U.S. government support for the mRNA Hub program; IRA drug price negotiation implementation; Emergency Access to Insulin Act, access to U.S. government funded medicines and vaccines, access to U.S. government funded medicines and vaccines, access to U.S. government funded medicines and vaccines; IRA drug price negotiation and inflationary rebate improvement legislation, access to U.S. government funded medicines and vaccines; U.S. government support for the mRNA Hub program, Affordable Insulin Now Act, Bayh-Dole march-in & royalty-free rights, Bayh-Dole march-in & royalty-free rights, IRA drug price negotiation implementation, IRA drug price negotiation implementation, NDAA biomedical R&D transparency, licensing, and pricing; access to U.S. government funded medicines and vaccines, PBM transparency Act, prescription pricing for the people act, IRA drug price negotiation implementation; IRA drug price negotiation and inflationary rebate improvement legislation, U.S. government support for the mRNA Hub program, U.S. government support for the mRNA Hub program; access to U.S. government funded medicines and vaccines.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN KNIEVEL | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.